Rally Meets Reality: iShares MSCI World ETF Faces Pharma Tariffs, an Index Overhaul, and a Possible SpaceX Shake-Up

BlackRock's iShares MSCI World ETF navigates pharma tariffs, Fed leadership change, index rebalancing, and growing fee pressure from rivals.

The iShares MSCI World ETF (URTH) notched a fresh 52-week high of $202.67 on Thursday, fueled by the relentless tech rally that has lifted Nvidia, Apple, and Microsoft for months. But beneath the surface, a rare convergence of structural forces is testing the resilience of BlackRock’s flagship global equity tracker. From Washington’s new pharmaceutical tariffs to a pending Fed leadership transition and the prospect of a SpaceX mega-IPO, the fund is navigating its most complex period since the pandemic-era distortions.

Roughly a tenth of URTH’s portfolio sits in healthcare, and that slice is about to feel the heat. Starting in late July, the US government will impose a tiered tariff system on imported patented drugs, hitting products from the European Union, Japan, South Korea and Switzerland with a 15 percent duty. British pharmaceutical goods face a 10 percent levy. For companies that lack existing US pricing agreements, the surcharge could skyrocket to 100 percent. Analysts at FactSet have already trimmed earnings forecasts for the sector, warning that the measures could add roughly half a percentage point to headline inflation while squeezing margins at European and Japanese drugmakers that carry significant weight in the MSCI World index.

Those inflationary ripples compound a macro environment that is already pressuring growth stocks. US consumer prices climbed 0.6 percent in April, pushing the annual rate to 3.8 percent. The Federal Reserve responded by holding its policy rate steady at 3.50–3.75 percent, though the 8–4 vote revealed an unusually deep split among policymakers. Futures markets have now fully priced out any rate cut for 2026, a stark reversal from earlier expectations. The uncertainty is amplified by the impending handover at the central bank’s helm: a new Fed chair is set to take office before June 15, just as the ETF’s ex-dividend date arrives.

Before that date, the index itself undergoes a significant reshuffling. MSCI’s latest quarterly review, published May 12, will take effect after the close on May 29, with a refined free-float methodology rolling out on June 1. Among the largest additions by market capitalisation are Medline A, MasTec and TechnipFMC. Because the previous adjustment was deliberately modest, this round of rebalancing demands heavier trading volume from physically replicating funds like URTH — real purchases and sales that could briefly amplify volatility.

In parallel, the fee war among ETF providers is heating up. Invesco recently slashed the expense ratio on its competing MSCI World product to 0.05 percent, and both UBS and BNP Paribas have followed suit with their own cuts. BlackRock charges 0.24 percent for URTH, a premium it justifies by pointing to the fund’s razor-thin tracking difference of just 0.02 percent. So far this year, net inflows have reached $770 million, but the cost gap could become more conspicuous for institutional allocators among the 297 rival funds in the category.

An even bigger wildcard looms on the horizon. SpaceX is reportedly preparing a roadshow in early June, potentially kicking off a process that could lead to an initial public offering in the second half of 2026. The valuation under discussion ranges from $1.75 trillion to $2.0 trillion, with an expected issuance volume exceeding $75 billion. If the rocket and satellite operator qualifies for fast-track inclusion in the Nasdaq-100 — index providers are already working on abbreviated admission timetables — then passive funds like URTH would be forced to buy billions of dollars’ worth of shares. That would further cement US dominance in the MSCI World, where American equities already account for more than 60 percent of assets and technology stocks alone represent nearly 29 percent, led by Nvidia at 5.57 percent and Apple at 4.58 percent.

Despite the pressures, Morningstar maintains its Gold rating on URTH, citing consistent quality and a 12-month total return of 29.14 percent. The three-year annualised performance stands at roughly 20 percent. Yet those same gains have pushed the fund’s relative strength index to 94.6 — deep into overbought territory — leaving it vulnerable to even minor shocks that could trigger profit-taking.

For investors tracking the ETF, the next few weeks pack an unusually dense calendar. The index rebalance lands on May 29, the free float methodology shifts on June 1, and the ex-dividend date arrives on June 15 — by which point the new Fed chair will already have taken the reins. Each event alone is manageable. Together, they test whether the world’s most popular equity ETF can keep its cool while the ground shifts beneath it.